AstraZeneca selects Salesforce Agentforce for global customer engagement

AstraZeneca (NASDAQ: AZN) has chosen Salesforce's (NYSE: CRM) Agentforce Life Sciences for Customer Engagement as its unified global platform to transform customer engagement with healthcare professionals, according to a Salesforce press release.

The biopharmaceutical company will implement Agentforce 360 for Life Sciences as an end-to-end engagement solution. The platform will consolidate healthcare professional insights across teams and provide next-best action recommendations for key account, reimbursement, and field teams. AstraZeneca plans to use the system to orchestrate automated digital campaigns across multiple channels based on customer preferences.

The implementation includes Model Context Protocol interoperability through Salesforce's Agent Fabric, which will allow AstraZeneca to coordinate internal and external agent actions across field engagement, commercial operations, and different brands and regions.

"This partnership with AstraZeneca represents a clear step towards building intelligent, agentic customer engagement in the life sciences industry with their selection of Agentforce Life Sciences for Customer Engagement," said Frank Defesche, SVP and GM of Life Sciences at Salesforce.

The platform aims to support AstraZeneca's operations in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology treatments. Salesforce states that more than 70 organizations have selected Agentforce Life Sciences.

The announcement expands Salesforce's existing relationship with AstraZeneca, building on previous technology implementations between the two companies.

You May Also Be Interested In